KRW 6250.0
(-2.5%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 128.35 Billion KRW | 21.22% |
2022 | 105.88 Billion KRW | 43.29% |
2021 | 73.89 Billion KRW | 183.87% |
2020 | 26.03 Billion KRW | 29.06% |
2019 | 20.17 Billion KRW | 34.42% |
2018 | 15 Billion KRW | 34.94% |
2017 | 11.12 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 133.17 Billion KRW | -8.23% |
2024 Q1 | 145.1 Billion KRW | 13.05% |
2023 Q3 | 112.39 Billion KRW | 9.9% |
2023 Q4 | 128.35 Billion KRW | 14.2% |
2023 FY | 128.35 Billion KRW | 21.22% |
2023 Q2 | 102.27 Billion KRW | -2.45% |
2023 Q1 | 104.83 Billion KRW | -0.99% |
2022 Q3 | 110.24 Billion KRW | 40.9% |
2022 Q4 | 105.88 Billion KRW | -3.95% |
2022 Q2 | 78.24 Billion KRW | 0.98% |
2022 Q1 | 77.47 Billion KRW | 4.84% |
2021 Q4 | 73.89 Billion KRW | 16.73% |
2021 Q3 | 63.3 Billion KRW | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 27.25 Billion KRW | -370.927% |
InBody Co.,Ltd | 24.62 Billion KRW | -421.322% |
Curexo Inc. | 6.94 Billion KRW | -1749.231% |
Seegene, Inc. | 221.05 Billion KRW | 41.934% |
i-SENS, Inc. | 195.32 Billion KRW | 34.285% |
Gencurix Inc. | 21.49 Billion KRW | -497.044% |
Sugentech Inc. | 20.73 Billion KRW | -519.116% |
L&C Bio Co., Ltd | 105.37 Billion KRW | -21.809% |